delivering “smarter” vaccine and anti-infective solutions. To accomplish this, we have developed key technologies and analytical strategies to facilitate our unique protection strategies:

- Their novel biofilm model that mimics the natural progression of disease for colonizing bacteria such Streptococcus pneumoniae and Staphylococcus aureus. Bioinformatics, in conjunction with our biofilm model, help to identify antigens associated with specific stages of disease progression.

- A novel coupling mechanism that removes the need for complex chemistry to manufacture polysaccharide conjugate vaccines.

- A broad-spectrum RNA-based therapy for treating influenza infections.

At Abcombi, we harness these potent tools to provide universally protective interventions for complex diseases such as pneumonia and influenza.